New eye drops may help older people see better

Summary: By the time most of us reach our 40s, our near vision begins to decline and we develop presbyopia. A new eye drop called Vuity claims to ease the symptoms of presbyopia, allowing people to have clearer vision without the need for glasses or surgery. Researchers are examining the potential benefits of using Vuity for people with presbyopia.

Source: The conversation

When people reach their 40s and beyond, their near vision begins to deteriorate. For many people, increasing the font size on a phone or maximizing the brightness on a computer is the only way to be able to read text.

This condition is known as presbyopiaand it affects about 128 million people in the United States and more than one billion people in the world.

In late 2021, the United States Food and Drug Administration approved a new eye drop drug to treat presbyopia. Inasmuch as optometristI was skeptical at first. Before the release of these eye drops – called Vuity – people would need glasses, contacts or eye surgery to relieve presbyopia. But after learning how these eye drops worked, I realized that for many people they could offer an easier and safer way to see clearly again.

How the eyes focus

Many parts of the human eye interact with incoming light to produce a clear image.

The first thing the light hits is the cornea, the transparent outer layer that initially bends the light. Then light passes through the iris and pupil, which can shrink or grow to let more or less light into the inside of the eye. It then moves through the lens, which further bends the light and focuses it precisely on the center of the retina. Finally, the light signal is transferred to the optic nerve at the back of the eye, for the brain to interpret as an image.

To produce a clear image, your eyes must adjust to the distance of an object. Your eyes do three big steps focus on objects close to your face: your eyes point to the object you want to look at, your lenses change shape and your pupils constrict.

Once you have aimed your gaze at what interests you, a small muscle in the eye contracts, which changes the shape of the lens to make it thicker. The thicker the lens, the more the light deforms as it passes through. At the same time, your pupils constrict to block some of the incoming light from other objects in the distance.

When light bounces off an object and enters your eye, the rays of light in the center provide a clear image. Blocking light scatter by constricting the pupil helps sharpen the image of nearby objects.

You can simulate this process using a camera on your cell phone. First, point the camera at something in the distance. Next, move your thumb into the image, holding it about 6 inches away. Your thumb will start out blurry, but as the camera lens changes shape, your thumb will come into focus.

What is presbyopia?

Presbyopia is the inability of the eyes to focus on near objects, resulting in blurry images. This starts when people are in their 40s and progresses until reaching a plateau around the age of 60.

Researchers know that age is the main driver of presbyopiabut there is an ongoing debate about the mechanical causes at its root.

One theory suggests that as lenses age, they become heavier and cannot change shape so easily. Another theory suggests that the the muscles that pull on the lens become weak with age. I suspect presbyopia is probably due to a combination of the two. Whatever the cause, the result is that when looking at nearby objects, people’s eyes are no longer able to bend incoming light enough to direct it to the center of the retina. Instead, light is focused to a location behind the retina, resulting in blurred vision.

How do eye drops work

Remember that there are two main things the eye does to focus on near objects: the lens changes shape and the pupil gets smaller. Since presbyopia limits the ability of the lens to change shape, these eye drops compensate by reducing the pupil.

This shows a man wearing glasses
Almost all people begin to develop blurred vision once they reach their 40s and 50s. Image is in public domain

Constricting the pupil reduces the amount of light scatter. This causes light entering the eye to be better focused on the retina, creating a wider range of distances where objects are in focus and allowing people to see both near and far objects clearly.

See also

This shows a cute little rat

After you put the drops in your eyes, it takes about 15 minutes for the active ingredient, pilocarpine, to start working. Pilocarpine is a drug that was first discovered in the late 1800s and can treat conditions such as glaucoma and ocular hypertension. The effect on the pupils lasts about six hours.

Smaller pupils mean less light enters the eye. Although this is not a problem during the day when there is plenty of sunlight, it can cause difficulty seeing in low light conditions. Besides these disadvantages, the most common side effects of the drops are headaches and red eyes.

Presbyopia in the future

Vuity is currently approved for use once a day in each eye. One bottle will cost around $80, requires a prescription, and will last almost a month if used daily. For some people, it could be a great alternative or complement to glasses or surgery.

While Vuity may be the first FDA-approved eye drops to treat presbyopia, researchers are studying a number of other approaches. Some develop eye drops that include nonsteroidal anti-inflammatory drugs to help constrict the pupil – similar to Vuity. Other teams are studying the drops that soften and reduce lens weight to promote easier focusing. Finally, some early research has shown that pulsed electrical stimulation of eye muscles can help strengthen them and improve people’s ability to bend their lenses.

The future of presbyopia treatment is exciting as researchers work on many potential ways to overcome this universal condition of old age. For now, Vuity – while not a magic bullet for everyone with presbyopia – is an innovative option and may be worth talking to your eye doctor about.

About this visual neuroscience and pharmacology research news

Author: Robert Bitner
Source: The conversation
Contact: Robert Bittner – The Conversation
Imagician: Image is in public domain

Leave a Comment